|
Palo Alto, CA, August 31, 2005 — Telik, Inc. (Nasdaq: TELK) announced that company management will provide corporate updates at three investment conferences in September 2005:
- Thomas Weisel Healthcare Tailwinds Conference: Wednesday, September 7, 4:25 pm EDT at the Four Seasons Hotel in Boston
- Bear Stearns 18 th Annual Healthcare Conference: Tuesday, September 13, 11:00 am EDT at the Grand Hyatt Hotel in New York City
- UBS Global Life Sciences Conference: Tuesday, September 27, 9:30 am EDT at the Grand Hyatt Hotel in New York City
A live webcast of each presentation will be available via the Telik website, www.telik.com. Archived webcasts will be accessible until the availability of the next presentation or for one week after the date of presentation.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA™ (TLK286), a tumor-activated small molecule product candidate. TELCYTA is in three Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. A second drug development candidate, TELINTRA™ (TLK199), is in Phase 2 clinical development in myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2005 Press Releases2004
Press Releases
2003
Press ReleasesEvents |
